Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | RORB | Q92753 | 1/20 | 0.36 |
| ▸ | NCS1 | P62166 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29013586 | 1.00 | HCRTR1 (0.41) | HCRTR1HCRTR2MAPK8MAPK10SORT1 | |
| SCHEMBL18291946 | 1.00 | HCRTR1 (0.41) | HCRTR1HCRTR2MAPK8MAPK10SORT1 | |
| SCHEMBL22511344 | 0.90 | HCRTR1 (0.41) | HCRTR1HCRTR2MAPK8MAPK10SORT1 | |
| SCHEMBL29393804 | 0.90 | MEN1 (0.37) | MAPK8MAPK10RXFP1MAPTMEN1 | |
| SCHEMBL203539 | 0.90 | MEN1 (0.37) | MAPK8MAPK10RXFP1MAPTMEN1 | |
| SCHEMBL18281652 | 0.90 | HCRTR1 (0.39) | HCRTR1HCRTR2MAPK8MAPK10SORT1 | |
| SCHEMBL18281651 | 0.90 | HCRTR1 (0.39) | HCRTR1HCRTR2MAPK8MAPK10SORT1 | |
| SCHEMBL24023024 | 0.90 | MAPK8 (0.36) | HCRTR1HCRTR2MAPK8MAPK10KDM4E | |
| SCHEMBL22511318 | 0.88 | HCRTR1 (0.40) | HCRTR1HCRTR2MAPK8MAPK10SORT1 | |
| SCHEMBL24023065 | 0.86 | MAPK8 (0.34) | HCRTR1HCRTR2MAPK8MAPK10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119330876-A | Preparation method of Flupyroxystrobin | 山东京博农化科技股份有限公司 | 2025-01-21 | — | — | CN | claimed |
| CN-119330876-A | Preparation method of Flupyroxystrobin | 山东京博农化科技股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-119111556-A | Insecticidal composition and application thereof | 青岛滕润翔检测评价有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-11882828-B2 | Mosquito vector control compositions, methods and products utilizing same | SYNGENTA PARTICIPATIONS AG (CH) | 2024-01-30 | — | — | US | disclosed |
| US-20230123440-A1 | MOSQUITO VECTOR CONTROL COMPOSITIONS, METHODS AND PRODUCTS UTILIZING SAME | SYNGENTA PARTICIPATIONS AG (CH) | 2023-04-20 | — | — | US | disclosed |
| US-11369113-B2 | Vector control compositions, methods and products utilizing same | SYNGENTA PARTICIPATIONS AG (CH) | 2022-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230123440-A1 | MOSQUITO VECTOR CONTROL COMPOSITIONS, METHODS AND PRODUCTS UTILIZING SAME | DDT, MLEC, MSMO1 | HCRTR1 1430/4885HCRTR2 2112/4885MAPK8 3810/4885 |
| US-11369113-B2 | Vector control compositions, methods and products utilizing same | DDT, MSMO1, MGLL | HCRTR1 2213/4885HCRTR2 2772/4885MAPK8 3527/4885 |
| US-11882828-B2 | Mosquito vector control compositions, methods and products utilizing same | DDT, MLEC, MSMO1 | HCRTR1 1430/4885HCRTR2 2112/4885MAPK8 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.